14 results on '"Amin, Sanober"'
Search Results
2. Ingenol mebutate-associated immune thrombocytopenic purpura.
- Author
-
Zuberi H and Amin SA
- Abstract
Competing Interests: None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
3. A novel intralesional treatment with Aureobasidium for recalcitrant warts.
- Author
-
Arora N and Amin SA
- Abstract
Competing Interests: None disclosed.
- Published
- 2023
- Full Text
- View/download PDF
4. Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series.
- Author
-
Karatas E, Nazim A, Patel P, Vaidya T, Drew GS, Amin SA, Keyes AA, Fonseca M, Mir A, and Halverstam CP
- Abstract
Competing Interests: None disclosed.
- Published
- 2023
- Full Text
- View/download PDF
5. Cutaneous adverse effects due to personal protective measures during COVID-19 pandemic: a study of 101 patients.
- Author
-
Mushtaq S, Terzi E, Recalcati S, Salas-Alanis JC, Amin S, and Faizi N
- Subjects
- Adult, COVID-19 epidemiology, COVID-19 transmission, COVID-19 virology, Communicable Disease Control instrumentation, Communicable Disease Control standards, Cross-Sectional Studies, Dermatitis, Contact etiology, Dermatitis, Occupational etiology, Female, Hand Hygiene methods, Humans, Male, Middle Aged, Personal Protective Equipment standards, SARS-CoV-2 pathogenicity, Soaps adverse effects, Young Adult, COVID-19 prevention & control, Dermatitis, Contact epidemiology, Dermatitis, Occupational epidemiology, Hand Hygiene standards, Pandemics prevention & control, Personal Protective Equipment adverse effects
- Abstract
Background: Coronavirus Disease 2019 (COVID-19) is a viral illness caused by the novel coronavirus SARS-CoV-2 which spreads via droplets from an infected person. There has been an unprecedented rise in the use of personal protective equipment and practice of personal hygiene measures against COVID-19. The extended use of protective measures (PM) can lead to ill effects on the skin. Our aim was to investigate PM-induced dermatoses amongst healthcare workers and the general population during the COVID-19 pandemic., Methods: A cross-sectional study was conducted over a period of 2 months. The study subjects were patients who presented to dermatology outpatient clinics or sought teleconsultation for skin problems related to the use of PMs against COVID-19. A detailed history was obtained and cutaneous examination was documented for all the patients in a pre-set proforma. Diagnoses of the adverse skin effects were formulated based upon history and clinical examination., Results: A total of 101 cases with cutaneous adverse effects due to the use of PMs against COVID-19 were included in the study. The general population and healthcare workers were affected similarly, comprising of 54.5% and 45.5%, respectively. The mean age of the study participants was 36.71 ± 15.72 years. The most common culprit material was soap and water (56.4%). Contact dermatitis was found to be the most common adverse effect in the majority of our patients (72.3%). The most common symptom reported was pruritus (45.5%). The wearing of personal protective equipment for a longer duration was significantly associated with multiple symptoms (P = 0.026)., Conclusion: The enhanced use of different PMs against COVID-19 can result in a variety of adverse skin effects. In our study, the use of soap and water was the most common culprit PM, and contact dermatitis was the most common adverse effect noted., (© 2020 the International Society of Dermatology.)
- Published
- 2021
- Full Text
- View/download PDF
6. VCAM-1 blockade delays disease onset, reduces disease severity and inflammatory cells in an atopic dermatitis model.
- Author
-
Chen L, Lin SX, Amin S, Overbergh L, Maggiolino G, and Chan LS
- Subjects
- Animals, Antibodies, Neutralizing immunology, Dermatitis, Atopic genetics, Dermatitis, Atopic metabolism, Dermatitis, Atopic pathology, Disease Models, Animal, E-Selectin biosynthesis, E-Selectin genetics, E-Selectin immunology, Eosinophils immunology, Eosinophils metabolism, Eosinophils pathology, Humans, Inflammation genetics, Inflammation immunology, Inflammation metabolism, Inflammation pathology, Keratin-14 biosynthesis, Keratin-14 genetics, Keratin-14 immunology, L-Selectin biosynthesis, L-Selectin genetics, L-Selectin immunology, Mast Cells immunology, Mast Cells metabolism, Mast Cells pathology, Membrane Glycoproteins biosynthesis, Membrane Glycoproteins genetics, Membrane Glycoproteins immunology, Mice, Mice, Knockout, NK Cell Lectin-Like Receptor Subfamily D genetics, NK Cell Lectin-Like Receptor Subfamily D immunology, NK Cell Lectin-Like Receptor Subfamily D metabolism, P-Selectin biosynthesis, P-Selectin genetics, P-Selectin immunology, Severity of Illness Index, Skin metabolism, Skin pathology, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes pathology, Vascular Cell Adhesion Molecule-1 genetics, Vascular Cell Adhesion Molecule-1 metabolism, Antibodies, Neutralizing pharmacology, Cell Movement immunology, Dermatitis, Atopic immunology, Skin immunology, Vascular Cell Adhesion Molecule-1 immunology
- Abstract
We investigated the functions of critical adhesion molecules ICAM-1 and VCAM-1 in a keratin-14 IL-4-transgenic (Tg) mouse model of atopic dermatitis, the skin lesions of which are characterized by prominent inflammatory cell infiltration, significantly increased mRNAs and proteins of ICAM-1, VCAM-1, E-selectin, P-selectin, L-selectin, and PSGL-1, and significantly increased numbers of dermal vessels expressing these adhesion molecules. We tested the hypotheses that deletion or blockade of these molecules may impede the inflammation by examining the disease progresses in the Tg mice crossed with ICAM-1-knockout mice and Tg mice received anti-VCAM-1-neutralizing antibody. Although the findings of the ICAM-1-knockout Tg mice (Tg/ICAM-1(-/-)) developed skin lesions similar to wide-type ICAM-1 Tg mice (Tg/ICAM-1(+/+)) were surprising, a compensatory mechanism may account for it: the frequency of VCAM-1 ligand, CD49d, on CD3(+) T cells in the lesional skin significantly increased in the Tg/ICAM-1(-/-) mouse, compared with the Tg/ICAM-1(+/+) mice. In contrast, anti-VCAM-1-treated Tg/ICAM-1(-/-) or Tg/ICAM-1(+/+) mice had significantly delayed onset of skin inflammation compared with isotype antibody-treated groups. Moreover, anti-VCAM-1 significantly reduced the skin inflammation severity in Tg/ICAM-1(+/+) mice, accompanied with reduction of mast cell, eosinophil, and CD3(+) T cell infiltration. VCAM-1 is more critical in developing skin inflammation in this model.
- Published
- 2010
- Full Text
- View/download PDF
7. Aromatase excess in cancers of breast, endometrium and ovary.
- Author
-
Bulun SE, Chen D, Lu M, Zhao H, Cheng Y, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Su E, Marsh E, Hakim A, Yin P, Ishikawa H, Amin S, Imir G, Gurates B, Attar E, Reierstad S, Innes J, and Lin Z
- Subjects
- Animals, Aromatase genetics, Breast Neoplasms genetics, Endometrial Neoplasms genetics, Female, Humans, Ovarian Neoplasms genetics, Aromatase metabolism, Breast Neoplasms enzymology, Endometrial Neoplasms enzymology, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Ovarian Neoplasms enzymology
- Abstract
Pathogenesis and growth of three common women's cancers (breast, endometrium and ovary) are linked to estrogen. A single gene encodes the key enzyme for estrogen biosynthesis named aromatase, inhibition of which effectively eliminates estrogen production in the entire body. Aromatase inhibitors successfully treat breast cancer, whereas their roles in endometrial and ovarian cancers are less clear. Ovary, testis, adipose tissue, skin, hypothalamus and placenta express aromatase normally, whereas breast, endometrial and ovarian cancers overexpress aromatase and produce local estrogen exerting paracrine and intracrine effects. Tissue-specific promoters distributed over a 93-kb regulatory region upstream of a common coding region alternatively control aromatase expression. A distinct set of transcription factors regulates each promoter in a signaling pathway- and tissue-specific manner. In cancers of breast, endometrium and ovary, aromatase expression is primarly regulated by increased activity of the proximally located promoter I.3/II region. Promoters I.3 and II lie 215 bp from each other and are coordinately stimulated by PGE(2) via a cAMP-PKA-dependent pathway. In breast adipose fibroblasts exposed to PGE(2) secreted by malignant epithelial cells, PKC is also activated, and this potentiates cAMP-PKA-dependent induction of aromatase. Thus, inflammatory substances such as PGE(2) may play important roles in inducing local production of estrogen that promotes tumor growth.
- Published
- 2007
- Full Text
- View/download PDF
8. Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
- Author
-
Amin SA, Huang CC, Reierstad S, Lin Z, Arbieva Z, Wiley E, Saborian H, Haynes B, Cotterill H, Dowsett M, and Bulun SE
- Subjects
- 3-Hydroxysteroid Dehydrogenases genetics, 3-Hydroxysteroid Dehydrogenases metabolism, Adipose Tissue cytology, Adolescent, Adult, Aldo-Keto Reductase Family 1 Member C3, Aromatase genetics, Aromatase metabolism, Cell Line, Tumor, Cells, Cultured, Culture Media, Conditioned pharmacology, Female, Fibroblasts drug effects, Humans, Hydroxyprostaglandin Dehydrogenases genetics, Hydroxyprostaglandin Dehydrogenases metabolism, Immunohistochemistry, Middle Aged, Polymerase Chain Reaction, RNA, Messenger biosynthesis, Breast Neoplasms metabolism, Estradiol metabolism, Fibroblasts metabolism, Gene Expression Profiling, Paracrine Communication genetics
- Abstract
Paracrine interactions between adipose fibroblasts and malignant epithelial cells are essential for structural and hormonal support of breast tumors. Factors derived from malignant epithelial cells inhibit adipogenic differentiation of fibroblasts and upregulate expression of aromatase, which stimulates estrogen synthesis and creates a localized, growth-stimulatory environment. Here, we characterized the gene expression profile of breast adipose fibroblasts in an in vitro model of malignancy to identify other paracrine interactions that support tumor growth. Primary breast adipose fibroblasts from cancer-free women were treated with conditioned media from malignant breast epithelial cells or normal breast epithelial cells, and differences in gene expression were identified by microarray. A total of 79 differentially regulated genes encoding cytokines, enzymes, angiogenic factors, cytoskeletal proteins, extra-cellular matrix remodeling proteins, signal transduction proteins and cell surface receptors were identified, and 6 of these were verified by real-time PCR. Among these, the expression of aldo-keto reductase family 1, member C3 (AKR1C3) was upregulated. AKR1C3 has multiple enzymatic properties, including conversion of estrone to estradiol and androstenedione to testosterone. Immunoreactive AKR1C3 was detected in epithelial and stromal components of benign lesions and ductal carcinomas in situ, and in 59.8% of epithelial and 69.6% of stromal cells in invasive breast carcinomas. AKR1C3 expression was significantly higher in myoepithelial cells surrounding the neoplastic epithelium of ductal carcinoma in situ compared with those surrounding benign epithelial lesions. Importantly, AKR1C3 and aromatase mRNA levels correlated positively in 61 malignant breast tumors (R=0.3967, p=0.00156). Malignant epithelial cell-conditioned medium significantly increased formation of testosterone and estradiol from androstenedione in breast adipose fibroblasts. In conclusion, malignant epithelial cell-derived factors significantly upregulate the enzymes AKR1C3 and aromatase that catalyze a series of complementary reactions to convert the circulating precursor androstenedione to biologically active estradiol in vitro in the stromal fibroblasts, and in vivo, in stromal component of breast tumors.
- Published
- 2006
- Full Text
- View/download PDF
9. A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts.
- Author
-
Deb S, Zhou J, Amin SA, Imir AG, Yilmaz MB, Lin Z, and Bulun SE
- Subjects
- Activating Transcription Factor 2 metabolism, Adipose Tissue, CCAAT-Binding Factor metabolism, CREB-Binding Protein metabolism, Cell Line, Tumor, Female, Fibroblasts, Humans, Liver cytology, Multiprotein Complexes metabolism, Ovary cytology, Phosphorylation, Placenta cytology, RNA, Messenger analysis, Aromatase genetics, Breast cytology, Breast Neoplasms pathology, Butyrates pharmacology, Gene Expression Regulation, Neoplastic drug effects, Promoter Regions, Genetic, Transcription, Genetic
- Abstract
The aromatase gene encodes the key enzyme for estrogen formation. Aromatase enzyme inhibitors eliminate total body estrogen production and are highly effective therapeutics for postmenopausal breast cancer. A distal promoter (I.4) regulates low levels of aromatase expression in tumor-free breast adipose tissue. Two proximal promoters (I.3/II) strikingly induce in vivo aromatase expression in breast fibroblasts surrounding malignant cells. Treatment of breast fibroblasts with medium conditioned with malignant breast epithelial cells (MCM) or a surrogate hormonal mixture (dibutyryl (Bt2)cAMP plus phorbol diacetate (PDA)) induces promoters I.3/II. The mechanism of promoter-selective expression, however, is not clear. Here we reported that sodium butyrate profoundly decreased MCM- or Bt2cAMP + PDA-induced promoter I.3/II-specific aromatase mRNA. MCM, Bt2cAMP + PDA, or sodium butyrate regulated aromatase mRNA or activity only via promoters I.3/II but not promoters I.1 or I.4 in breast, ovarian, placental, and hepatic cells. Mechanistically, recruitment of phosphorylated ATF-2 by a CRE (-211/-199, promoter I.3/II) conferred inductions by MCM or Bt2cAMP + PDA. Chromatin immunoprecipitation-PCR and immunoprecipitation-immunoblotting assays indicated that MCM or Bt2cAMP + PDA stabilized a complex composed of phosphorylated ATF-2, C/EBPbeta, and cAMP-response element-binding protein (CREB)-binding protein in the common regulatory region of promoters I.3/II. Overall, histone acetylation patterns of promoters I.3/II did not correlate with sodium butyrate-dependent silencing of promoters I.3/II. Sodium butyrate, however, consistently disrupted the activating complex composed of phosphorylated ATF-2, C/EBPbeta, and CREB-binding protein. This was mediated, in part, by decreased ATF-2 phosphorylation. Together, these findings represent a novel mechanism of sodium butyrate action and provide evidence that aromatase activity can be ablated in a signaling pathway- and cell-specific fashion.
- Published
- 2006
- Full Text
- View/download PDF
10. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
- Author
-
Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, Tamura M, Langoi D, and Deb S
- Subjects
- Animals, Aromatase genetics, Aromatase Inhibitors pharmacology, Breast Neoplasms metabolism, Female, Humans, Ovarian Diseases metabolism, Promoter Regions, Genetic, Aromatase biosynthesis, Breast Neoplasms enzymology, Estrogens metabolism, Gene Expression Regulation, Enzymologic, Ovarian Diseases enzymology
- Abstract
A single gene encodes the key enzyme for estrogen biosynthesis termed aromatase, inhibition of which effectively eliminates estrogen production. Aromatase inhibitors successfully treat breast cancer and endometriosis, whereas their roles in endometrial cancer, uterine fibroids, and aromatase excess syndrome are less clear. Ovary, testis, adipose tissue, skin, hypothalamus, and placenta express aromatase normally, whereas breast and endometrial cancers, endometriosis, and uterine fibroids overexpress aromatase and produce local estrogen that exerts paracrine and intracrine effects. Tissue-specific promoters distributed over a 93-kilobase regulatory region upstream of a common coding region alternatively control aromatase expression. A distinct set of transcription factors regulates each promoter in a signaling pathway- and tissue-specific manner. Three mechanisms are responsible for aromatase overexpression in a pathologic tissue versus its normal counterpart. First, cellular composition is altered to increase aromatase-expressing cell types that use distinct promoters (breast cancer). Second, molecular alterations in stromal cells favor binding of transcriptional enhancers versus inhibitors to a normally quiescent aromatase promoter and initiate transcription (breast/endometrial cancer, endometriosis, and uterine fibroids). Third, heterozygous mutations, which cause the aromatase coding region to lie adjacent to constitutively active cryptic promoters that normally transcribe other genes, result in excessive estrogen formation owing to the overexpression of aromatase in many tissues.
- Published
- 2005
- Full Text
- View/download PDF
11. Estrogen regulates expression of tumor necrosis factor receptors in breast adipose fibroblasts.
- Author
-
Deb S, Amin S, Imir AG, Yilmaz MB, Suzuki T, Sasano H, and Bulun SE
- Subjects
- Adipose Tissue cytology, Antigens, CD genetics, Breast cytology, Cells, Cultured, Estradiol pharmacology, Female, Humans, RNA, Messenger antagonists & inhibitors, Receptors, Estrogen metabolism, Receptors, Tumor Necrosis Factor antagonists & inhibitors, Receptors, Tumor Necrosis Factor genetics, Receptors, Tumor Necrosis Factor, Type I, Receptors, Tumor Necrosis Factor, Type II, Tumor Necrosis Factor-alpha pharmacology, Adipose Tissue metabolism, Antigens, CD metabolism, Breast metabolism, Estrogens physiology, Fibroblasts metabolism, Receptors, Tumor Necrosis Factor metabolism
- Abstract
In breast cancer, a dense layer of undifferentiated fibroblasts is formed around malignant breast epithelial cells and referred to as desmoplastic reaction. These cells provide structural and functional support for tumor growth. Aromatase, the key enzyme in the biosynthesis of estrogen, is overexpressed in these undifferentiated fibroblasts, producing large quantities of estrogen, which in turn influences the growth and progression of malignant epithelial cells. We previously demonstrated that malignant epithelial cells produce large amounts of TNFalpha, which inhibit the differentiation of breast fibroblasts. TNF action is mediated by its two receptors (TNFRs), TNFR1, which mediates inhibition of adipocyte differentiation, and TNFR2, which was linked to the proliferation of thymocytes. We present evidence here that estrogen modulates the synthesis of receptors for TNF in human adipose fibroblasts (HAFs) from breast tissue in a paracrine fashion, which may serve as a mechanism for the inhibition of adipocyte differentiation in breast cancer. Estradiol (E(2)) treatment increased TNFR1 mRNA and protein levels in primary HAFs in a dose- and time-dependent manner, which could be reversed by the estrogen antagonist ICI182,780. Interestingly, higher concentration of E(2) inhibited whereas lower concentrations stimulated TNFR2 mRNA levels in HAFs. To investigate the specific roles of TNFRs in adipocyte differentiation, we incubated breast HAFs with receptor selective muteins of TNF. TNFR1-selective mutein decreased mRNA levels of aP2, a marker for adipogenic differentiation. This antiadipogenic effect was enhanced by cotreatment with E(2). We conclude that high levels of estrogen found in breast tumors promote the antiadipogenic action of TNF on breast adipose fibroblasts by selectively up-regulating TNFR1, which may be a critical mechanism for desmoplastic reaction.
- Published
- 2004
- Full Text
- View/download PDF
12. Aromatase and endometriosis.
- Author
-
Bulun SE, Fang Z, Imir G, Gurates B, Tamura M, Yilmaz B, Langoi D, Amin S, Yang S, and Deb S
- Subjects
- Endometriosis drug therapy, Enzyme Inhibitors therapeutic use, Estrogens biosynthesis, Female, Gene Expression Regulation, Humans, Stromal Cells enzymology, Aromatase metabolism, Endometriosis enzymology
- Abstract
Aromatase p450 (p450arom) is the key enzyme for biosynthesis of estrogen, which is an essential hormone for the establishment and growth of endometriosis. There is no detectable aromatase enzyme activity in normal endometrium; therefore, estrogen is not locally produced in endometrium. Endometriosis tissue, however, contains very high levels of aromatase enzyme, which leads to production of significant quantities of estrogen. Moreover, one of the best-known mediators of inflammation and pain, prostaglandin E (2), strikingly induces aromatase enzyme activity and formation of local estrogen in this tissue. Additionally, estrogen itself stimulates cyclo-oxygenase-2 and therefore increases the formation of prostaglandin E (2) in endometriosis. We were able to target this positive feedback cycle in endometriosis using aromatase inhibitors. In fact, pilot trials showed that aromatase inhibitors could decrease pelvic pain associated with endometriosis.
- Published
- 2004
- Full Text
- View/download PDF
13. WT1 and DAX-1 regulate SF-1-mediated human P450arom gene expression in gonadal cells.
- Author
-
Gurates B, Amsterdam A, Tamura M, Yang S, Zhou J, Fang Z, Amin S, Sebastian S, and Bulun SE
- Subjects
- Amino Acid Motifs, Animals, Aromatase metabolism, Base Sequence, Cell Line, Consensus Sequence, DAX-1 Orphan Nuclear Receptor, Down-Regulation, Female, Fushi Tarazu Transcription Factors, Gene Expression Regulation, Genes, Wilms Tumor, Humans, Male, Mice, Molecular Sequence Data, Plasmids, Promoter Regions, Genetic, Sertoli Cells metabolism, Steroidogenic Factor 1, Transcriptional Activation, Aromatase genetics, DNA-Binding Proteins physiology, Gonads metabolism, Receptors, Retinoic Acid physiology, Repressor Proteins physiology, Transcription Factors physiology, WT1 Proteins physiology
- Abstract
Binding activity of steroidogenic factor-1 (SF-1) to promoters of the majority of steroidogenic genes in response to gonadotropins is a critical mechanism that regulates steroidogenesis in gonads. Thus, the modulation of SF-1 action may be essential for the differential regulation of formation of sex steroids in the ovary. Aromatase P450 (P450arom) is the rate-limiting enzyme for estrogen formation. In this study, we characterize another nuclear receptor half site in the gonadal aromatase promoter which we show to be important for aromatase regulation. We also show herein that the stimulation of P450arom promoter activity by SF-1 in ovarian granulosa, testicular Sertoli and JEG-3 choriocarcinoma cells is inhibited by two transcription factors, Wilms' tumor suppressor gene (WT1) and dosage sensitive sex reversal adrenal hypoplasia congenita critical region on the X chromosome gene 1 (DAX-1). Given the characterized roles of these transcription factors in gonadal development and function, modulation of SF-1 action by WT1 and DAX-1 may represent an important key mechanism in steroidogenesis.
- Published
- 2003
- Full Text
- View/download PDF
14. Mechanisms of excessive estrogen formation in endometriosis.
- Author
-
Bulun SE, Gurates B, Fang Z, Tamura M, Sebastian S, Zhou J, Amin S, and Yang S
- Subjects
- Aromatase genetics, Aromatase metabolism, Aromatase Inhibitors, Endometriosis drug therapy, Endometriosis etiology, Enzyme Inhibitors therapeutic use, Estradiol metabolism, Female, Gene Expression, Humans, Inflammation etiology, Inflammation metabolism, Models, Biological, RNA, Messenger genetics, RNA, Messenger metabolism, Signal Transduction, Endometriosis metabolism, Estrogens biosynthesis
- Abstract
Estrogen is produced in a number of human tissues including the ovary, placenta and extraglandular sites such as adipose tissue, skin and the brain. Aromatase is the key enzyme that regulates estrogen formation in these tissues. Aromatase activity is not detectable in normal endometrium. In contrast, aromatase is expressed aberrantly in endometriosis and is stimulated by PGE(2). This results in local production of estrogen, which induces PGE(2) formation and establishes a positive feedback cycle. Another abnormality in endometriosis, i.e. deficient 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 2 expression, impairs the inactivation of estradiol to estrone. These molecular aberrations collectively favor accumulation of increasing quantities of estradiol and PGE(2) in endometriosis. The clinical relevance of these findings was exemplified by the successful treatment of an unusually aggressive case of postmenopausal endometriosis using an aromatase inhibitor.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.